Abstract | BACKGROUND: To evaluate the safety and effectiveness of empagliflozin in routine clinical settings, we collected and assessed the clinical profiles of Korean patients with type 2 diabetes mellitus. METHODS: RESULTS: The incidence rate of ADRs was 5.14% in the safety dataset (n=3,231). Pollakiuria, pruritis genital, and weight loss were the most common ADRs. ADRs of special interest accounted for only 1.18%, and there were no serious events that led to mortality or hospitalization. In the effectiveness data set (n=2,567), empagliflozin significantly reduced the mean HbA1c level and body weight during the study period by -0.68%±1.39% and -1.91±3.37 kg (both P<0.0001), respectively. In addition, shorter disease duration, absence of dyslipidemia, and higher baseline HbA1c levels were identified as the clinical features characteristic of a "responder" to empagliflozin therapy. CONCLUSION:
|
Authors | Jun Sung Moon, Nam Hoon Kim, Jin Oh Na, Jae Hyoung Cho, In-Kyung Jeong, Soon Hee Lee, Ji-Oh Mok, Nan Hee Kim, Dong Jin Chung, Jinhong Cho, Dong Woo Lee, Sun Woo Lee, Kyu Chang Won |
Journal | Diabetes & metabolism journal
(Diabetes Metab J)
Vol. 47
Issue 1
Pg. 82-91
(01 2023)
ISSN: 2233-6087 [Electronic] Korea (South) |
PMID | 35722684
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- empagliflozin
- Glycated Hemoglobin
- Hypoglycemic Agents
|
Topics |
- Humans
- Body Weight
- Diabetes Mellitus, Type 2
(drug therapy, epidemiology)
- Glycated Hemoglobin
- Hypoglycemic Agents
(therapeutic use)
- Product Surveillance, Postmarketing
- Republic of Korea
(epidemiology)
|